A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study (Q46688401)

24 December 2017

title

A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study (English)

1 reference

24 December 2017

1 reference

5

Serena Tonstad

1 reference

24 December 2017

author name string

Anton F H Stalenhoef

1

1 reference

24 December 2017

Christie M Ballantyne

2

1 reference

24 December 2017

Cinzia Sarti

3

1 reference

24 December 2017

Jan Murin

4

1 reference

24 December 2017

Helen Rose

6

1 reference

24 December 2017

Wim Wilpshaar

7

1 reference

24 December 2017

publication date

5 September 2005

1 reference

24 December 2017

published in

European Heart Journal

1 reference

24 December 2017

volume

26

1 reference

24 December 2017

issue

24

1 reference

24 December 2017

page(s)

2664-2672

1 reference

24 December 2017

Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women

cites work

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Hypertriglyceridemia, insulin resistance, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Beyond lipid lowering: the role of statins in vascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Clinical application of C-reactive protein for cardiovascular disease detection and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Safety of HMG-CoA reductase inhibitors: focus on atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

21 January 2018

Safety of rosuvastatin

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Risk for myopathy with statin therapy in high-risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHI482

21 January 2018

Identifiers

DOI

10.1093/EURHEARTJ/EHI482

1 reference

24 December 2017

1 reference

24 December 2017